Do you want to read an article? Please log in or register.
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib
Lung, Respiratory and Thoracic Cancer
